Related Experiment Video
Updated: Jul 20, 2026

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
Inhibition of hepatitis B virus X gene expression by 10-23 DNAzymes
1Key Laboratory of Infectious Diseases, Ministry of Public Health of China, Institute of Infectious Diseases, First Affiliated Hospital, College of Medical Sciences, Zhejiang University, Qingchun Road 79, Hangzhou, Zhejiang 310003, China.
Abstract:
The X protein (HBx) of human hepatitis B virus (HBV) is a transcriptional activator protein. The HBx protein plays an important role in viral replication in HBV infected cells and the liver diseases including hepatitis, cirrhosis and hepatocellular carcinoma (HCC). Therefore, the repression of HBx gene expression by 10-23 DNAzymes might be a good way to inhibit HBV replication and counteract HBV-related liver diseases. We designed three 10-23 DNAzymes with different substrate-recognition domains. When each of the 10-23 DNAzymes were cotransfected into human AD293 cells with HBx-EGFP expression plasmid, they could all reduce the level of HBx mRNA as well as the HBx-EGFP protein. These results suggest that the 10-23 DNAzymes might be used for gene therapy of liver diseases caused by HBV.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Antiviral Nucleoside Inhibitors
Inhibitors Of Virion Release
Viruses with RNA Genomes
Inhibitors of Virion Maturation and Assembly

